Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 2/20 | 0.61 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.58 |
| ▸ | SHBG | P04278 | 3/20 | 0.58 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.58 |
| ▸ | SERPINA6 | P08185 | 2/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.58 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.58 |
| ▸ | PGR | P06401 | 1/20 | 0.58 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.58 |
| ▸ | MGAM | O43451 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2545024 | 1.00 | AR (0.61) | ARCYP19A1SHBGGPBAR1SERPINA6 | |
| SCHEMBL7193192 | 1.00 | AR (0.61) | ARCYP19A1SHBGGPBAR1SERPINA6 | |
| SCHEMBL2281371 | 1.00 | AR (0.61) | ARCYP19A1SHBGGPBAR1SERPINA6 | |
| SCHEMBL867595 | 1.00 | AR (0.61) | ARCYP19A1SHBGGPBAR1SERPINA6 | |
| SCHEMBL15259496 | 1.00 | AR (0.61) | ARCYP19A1SHBGGPBAR1SERPINA6 | |
| SCHEMBL8898529 | 0.86 | AR (0.45) | ARCYP19A1SHBGGPBAR1SERPINA6 | |
| SCHEMBL21807712 | 0.86 | AR (0.45) | ARCYP19A1SHBGGPBAR1SERPINA6 | |
| SCHEMBL23378235 | 0.84 | AR (0.44) | ARCYP19A1SHBGGPBAR1SERPINA6 | |
| SCHEMBL2510574 | 0.84 | AKR1B10 (0.61) | ARSHBGGPBAR1SERPINA6CYP3A4 | |
| SCHEMBL6839045 | 0.84 | AKR1B10 (0.49) | GPBAR1CYP3A4LMNACYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050113354-A1 | Bioavailable prodrugs of androgenic steroids and related method | ROBERTS WILLIAM J (US) | 2005-05-26 | — | — | US | claimed |
| US-20030134830-A1 | Bioavailable prodrugs of androgenic steroids and related method | BIOTEST LABORATORIES, LLC | 2003-07-17 | — | — | US | claimed |
| US-20030134828-A1 | Composition and method for increasing in vivo androgen concentration | ROBERTS WILLIAM J (US) | 2003-07-17 | — | — | US | claimed |
| US-20020183532-A1 | Bioavailable prodrugs of androgenic steroids and related method | BIOTEST LABORATORIES, LLC | 2002-12-05 | — | — | US | claimed |
| US-6391868-B2 | Use of 5-alpha-androst-1-en-3,17-dione to increase the level of the anabolic/androgenic hormone 17-beta-hydroxy-5-alpha-androst-1-en-3-one in humans | LPT RESEARCH, INC. | 2002-05-21 | — | — | US | claimed |
| US-20010056087-A1 | Use of 5alpha-androst-1en-3,17-diol to increase the level of the anabolic/androgenic hormone 17beta-hydroxy-5alpha-androst-1-en-3-one in humans | ARNOLD PATRICK (US) | 2001-12-27 | — | — | US | claimed |
| US-20010041698-A1 | Use of 5alpha -androst-1-en-3,17-dione to increase the level of the anabolic/androgenic hormone 17beta-hydroxy-5alpha-androst-1-en-3-one in humans | ARNOLD PATRICK (US) | 2001-11-15 | — | — | US | claimed |
| US-20210199646-A1 | SAMPLE DEPLETION AND ENRICHMENT TO IMPROVE THE QUALITY OF DIAGNOSTIC TEST RESULTS | VERAVAS, INC. | 2021-07-01 | — | — | US | disclosed |
| US-10948484-B2 | Sample depletion and enrichment to improve the quality of diagnostic test results | VERAVAS, INC. (US) | 2021-03-16 | — | — | US | disclosed |
| EP-3172566-B1 | SAMPLE ANALYSING DEVICE | INTELLIGENT FINGERPRINTING LTD (GB) | 2019-10-16 | — | — | EP | disclosed |
| US-20190137484-A9 | Sample depletion and enrichment to improve the quality of diagnostic test results | VERAVAS, INC. (US) | 2019-05-09 | — | — | US | disclosed |
| US-10265328-B2 | C-19 steroids for specific therapeutic uses | PROCIMA GMBH (DE) | 2019-04-23 | — | — | US | disclosed |
| US-20180292394-A1 | Sample depletion and enrichment to improve the quality of diagnostic test results | SOLDO JOSHUA CAINE (US) | 2018-10-11 | — | — | US | disclosed |
| US-20010041698-A1 | Use of 5alpha -androst-1-en-3,17-dione to increase the level of the anabolic/androgenic hormone 17beta-hydroxy-5alpha-androst-1-en-3-one in humans | ARNOLD PATRICK (US) | 2001-11-15 | — | — | US | disclosed |
| US-20010041698-A1 | Use of 5alpha -androst-1-en-3,17-dione to increase the level of the anabolic/androgenic hormone 17beta-hydroxy-5alpha-androst-1-en-3-one in humans | ARNOLD PATRICK (US) | 2001-11-15 | — | — | US | disclosed |
| US-20010041698-A1 | Use of 5alpha -androst-1-en-3,17-dione to increase the level of the anabolic/androgenic hormone 17beta-hydroxy-5alpha-androst-1-en-3-one in humans | ARNOLD PATRICK (US) | 2001-11-15 | — | — | US | disclosed |
| EP-0700291-A4 | 15-SUBSTITUTED 4-AZASTEROIDS | MERCK & CO INC (US) | 1996-07-03 | — | — | EP | disclosed |
| EP-0700291-A1 | 15-SUBSTITUTED 4-AZASTEROIDS | MERCK & CO. INC. (US) | 1996-03-13 | — | — | EP | disclosed |
| EP-0423842-A2 | Steroids and therapeutic compositions containing same | Research Corporation (US) | 1991-04-24 | — | — | EP | disclosed |
| US-3990956-A | Electrochemical reduction of α,β-unsaturated keto steroids | SCHERING AKTIENGESELLSCHAFT (DT) | 1976-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10265328-B2 | C-19 steroids for specific therapeutic uses | AR, CYP17A1, SHBG | AR 1/4885CYP19A1 14/4885SHBG 3/4885 |
| US-20030134828-A1 | Composition and method for increasing in vivo androgen concentration | SHBG, CYP21A2, CYP19A1 | AR 6/4885CYP19A1 3/4885SHBG 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.